Dax in the Evening

[Oscar Reed]

Okay volume on the way up in the early part of the session.

Pull back now and waiting for the US lead.

Got some technical limit sells above 9,900 for over night.

 

[Oscar Reed]

Last night was so strange
Most of the time direct and market makers i watch have a 1 to 4 variance, never out to 25.
But the price will follow each other up and down the chart like sheep.
Last night one broker price was going up and the other going down.
Had me confused, not hard.
Almost seemed the direct market had the wrong price.
Got some overnights fills above 9,900

 

[Oscar Reed]

Trying to short the DAX while she got her Flash dance pants on.
Bad move.
Not in the mood for trading today.

 

[Oscar Reed]

@darktone

Like it just need to watch a couple of times to get more out of it.

And get my head around if that's the correct word's for the video.

 

[Oscar Reed]

No let in volume.

Any slight pull back being purchased.

Any US pull back this market will be picked up today.

Over night tech buys below 10,000

 

[Oscar Reed]

10,000 battle is on

 

[ItsABUY]

Immune Pharmaceuticals Announces 2016 Immuno-Oncology Plan

NEW YORK, (UPTICK Newswire – Jan. 12, 2016) — Immune Pharmaceuticals Inc. (IMNP), “Immune”, a clinical-stage biopharmaceutical company, announced today that it has prioritized its oncology development programs for 2016. Immune’s oncology pipeline is comprised of three small molecules in mid to late stage clinical development and two novel technology platforms.

Dr. Daniel Teper, Immune’s CEO commented: “We are focusing on disruptive technologies and targets that have the potential to change patient outcomes. In 2016 our goal is to generate data that will support partnerships and accelerate development thereby helping us bring life-changing therapies to cancer patients”.

The company’s Immuno-Oncology programs for 2016 include the following assets and data milestones:

Ceplene® in combination with low dose IL-2 is approved in 27 countries in Europe for remission maintenance and prevention of relapse in adults with Acute Myeloid Leukemia, an orphan indication with poor survival prognosis and no new therapy for many years. Ceplene® protects T Cell and Natural Killer (NK) cells against inactivation and apoptosis enabling IL-2 to eliminate leukemia cells and protect against relapse. Results of a post-marketing study conducted in Europe in a biomarker-defined sub-population are expected in 2016.
Azixa® and Crolibulin are two new vascular disruptive agents (VDAs) with additional anti-tumor activity demonstrated in preclinical studies. Both drugs have shown promising initial efficacy in phase I/II clinical trials in multiple solid tumors, including glioblastoma. Combination studies of VDAs with immune check-point inhibitors are underway in preclinical tumor models. These efforts will help provide the rationale for the design of a new phase II combination clinical study with a check point inhibitor.
Immune’s two novel technology platforms, bispecific antibodies and immuno-nanoparticles(NanomAbs®), will be focused on immuno-oncology and applied to novel targets including immune check points. Pre-clinical validation with selected immune check point targets is planned in 2016.
About Immune Pharmaceuticals:

Immune Pharmaceuticals (IMNP) applies a personalized approach to treating and developing novel, highly-targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer. Immune’s lead product candidate, bertilimumab, is in phase II clinical development for moderate-to-severe ulcerative colitis as well as for bullous pemphigoid, an orphan auto-immune dermatological condition. Other indications being considered for development include atopic dermatitis, Crohn’s disease, severe asthma and NASH (an inflammatory liver disease). Immune recently expanded its portfolio in immuno-dermatology with topical nano-formulated cyclosporine-A for the treatment of psoriasis and atopic dermatitis. Immune’s oncology pipeline includes, bispecific antibodies, nanotherapeutics (NanomAbs®), and several mid-to-late stage small molecules. Immune’s non-core pipeline includes AmiKet®, a late clinical stage drug candidate for the treatment of neuropathic pain. For more information, visit Immune’s website at www.immunepharmaceuticals.com, the content of which is not a part of this press release.

Forward-Looking Statements
This news release and any oral statements made with respect to the information contained in this news release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You are urged to consider statements that include the words “may,” “will,” “would,” “could,” “should,” “believes,” “estimates,” “projects,” “potential,” “expects,” “plans,” “anticipates,” “intends,” “continues,” “forecast,” “designed,” “goal” or the negative of those words or other comparable words to be uncertain and forward-looking. Such forward-looking statements include statements that express plans, anticipation, intent, contingency, goals, targets, future development and are otherwise not statements of historical fact. These statements are based on our current expectations and are subject to risks and uncertainties that could cause actual results or developments to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Factors that may cause actual results or developments to differ materially include, but not limited to: the risks associated with the adequacy of our existing cash resources and our ability to continue as a going concern; the risks associated with our ability to continue to meet our obligations under our existing debt agreements; the risk that clinical trials for bertilimumab or AmiKet will not be successful; the risk that bertilimumab, AmiKet or compounds arising from our NanomAbs program will not receive regulatory approval or achieve significant commercial success; the risk that we will not be able to find a partner to help conduct the Phase III trials for AmiKet on attractive terms, on a timely basis or at all; the risk that our other product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later-stage clinical trials; the risk that we will not obtain approval to market any of our product candidates; the risks associated with dependence upon key personnel; the risks associated with reliance on collaborative partners and others for further clinical trials, development, manufacturing and commercialization of our product candidates; the cost, delays and uncertainties associated with our scientific research, product development, clinical trials and regulatory approval process; our history of operating losses since our inception; the highly competitive nature of our business; risks associated with litigation; and risks associated with our ability to protect our intellectual property. These factors and other material risks are more fully discussed in our periodic reports, including our reports on Forms 8-K, 10-Q and 10-K and other filings with the U.S. Securities and Exchange Commission. You are urged to carefully review and consider the disclosures found in our filings, which are available at www.sec.gov or at www.immunepharmaceuticals.com. You are cautioned not to place undue reliance on any forward-looking statements, any of which could turn out to be wrong due to inaccurate assumptions, unknown risks or uncertainties or other risk factors. We expressly disclaim any obligation to publicly update any forward looking statements contained herein, whether as a result of new information, future events or otherwise, except as required by law.
https://upticknewswire.com/immune-pharmaceuticals-announces-2016-immuno-oncology-plan/ :clap::clap:

 

[Oscar Reed]

NEW YORK, (UPTICK Newswire – Jan. 12, 2016) — Immune Pharmaceuticals Inc. (IMNP), “Immune”, a clinical-stage biopharmaceutical company, announced today that it has prioritized its oncology development programs for 2016. Immune’s oncology pipeline is comprised of three small molecules in mid to late stage clinical development and two novel technology platforms.

Dr. Daniel Teper, Immune’s CEO commented: “We are focusing on disruptive technologies and targets that have the potential to change patient outcomes. In 2016 our goal is to generate data that will support partnerships and accelerate development thereby helping us bring life-changing therapies to cancer patients”.

@ItsABUY

Hope you been short for the last 6 months.

 

[Oscar Reed]

Bit of volume drop off today on the way up.

Been running hard this week.

Needs a bit of back and fill.

 

[Oscar Reed]

12 hours ago was buy into weakness.

Now it's sell into strength.

Going to have problems getting back past 9,920, should be hit with a wave of selling in that area.

Anyway got some good areas to work with.

Struggling with getting the size up this week. part of that is me and just doing the work(screen time).

Got the account ticking along now in 2016, to the next draw down.

 

[Oscar Reed]

Got my technical limit sells in.
No buys at this stage, wait for the market to open.
And the buyers to build, then try and hop on board the moves.
Even had to use a 15 min chart today because of the big moves.

Now just sit and wait.

 

[Oscar Reed]

Early limits booked and reloaded.

 

[Oscar Reed]

Ezzetrader sent me an e-mail.
Might check it out and let you know.
See if old Charlie boy can really trade.
Not paying the *******s.


Next Wednesday and Thursday, the 20th and 21st of January, we're opening up our trading room to you for two days access!

If you would like to see what we do on a daily basis and see our community in action, just email me and I'll set up your passwords next week so you can enter the room.

If you just title your email to me '2 day's room access' and give me your name, I can then get you all set for next week!

 

[Oscar Reed]

Volume all over the shop, loads of gaps in bid/ask price.
Not leaving any over night orders, this market shoot up and down a few hundred points very quickly.
Plus I cut my early shorts too soon, so sulking at the moment.
Mind you mind might I sneak out of bed for a 2am check.:whistling

 

[Oscar Reed]

V bottom anyone.

Goodnight DAX

 

[Oscar Reed]

No Trading today.

It's the CBFT holiday,

Well done DAX on the 300 point move higher.

They used to play at the end of Cambridge Utd games when they won.

 

[Oscar Reed]

Sneaked in a few after midnight trades.
The futures delivered in Asia.
More luck than judgement.
But a good way to finish the week.

 

[Oscar Reed]

Solid volume both ways and no gaps in price.
Just means we go up and down fast.

 

[Oscar Reed]

 

[Oscar Reed]